10 Reasons Why $GLSI is a buy right now!
1) 
GLSI had 100% success preventing breast cancer recurrence over the last 6 years in their clinical trial 1 & trial 2.
2) Management team has 35+ years working together on several other successful biotech startups. They’re just repeating a proven biotech business model.
3) Executive team already multi-millionaires from previous successful ventures, they have not paid themselves a salary since startingGLSI, and thus the CEO stated on video a few months ago they do NOT need to raise additional capital.
4) CEO ofGLSI bought up 75% of the shares of GLSI…high insider conviction!
5) The drug originally developed by U.S. Gov, the CEO of GLSI bought the rights to the drug from the gov under the condition that GLSI would finish it’s development through all the clinical trials. The CEO notes this on a 2020 Benzinga video presentation.
6) MD Anderson Cancer Research facility in Houston, TX has performed all ofGLSI’s clinical trails, and is performing the final trial 3 as well. (MD Anderson = world’s best cancer research facility in the world, very difficult to get MD Anderson to accept performing clinical trials on a new biotech drug. Most biotech companies don’t have this resource, GLSI does.
7) See price jump to $158 when the 1st half of data was presented at the American Association of Cancer Research in Dec 2020, showing 100% success over last 6 years in trails 1 & 2.
8) See video above ofGLSI C.E.O. on Benzinga PowerHour March 11 saying the evening of Thursday April 8 they will be releasing the 2nd half of the data (immune response data) from their American Association of Cancer Research presentation in April 2021. This is the last piece of data for GLSI to start phase III trials for FDA approval. MAJOR CATALYST!
9) Notice the stock price has been significantly increasing the past few days in anticipation of the immune response data being released April 8 evening. $150+ price estimate on Friday April 9.
10) My metrics giveGLSI a 93% probability of success getting FDA approval, with a price of $400-500+ once approved. Recent stock price moves show many others agree with my estimation.
GLSI had 100% success preventing breast cancer recurrence over the last 6 years in their clinical trial 1 & trial 2.2) Management team has 35+ years working together on several other successful biotech startups. They’re just repeating a proven biotech business model.
3) Executive team already multi-millionaires from previous successful ventures, they have not paid themselves a salary since starting
GLSI, and thus the CEO stated on video a few months ago they do NOT need to raise additional capital.4) CEO of
GLSI bought up 75% of the shares of GLSI…high insider conviction!5) The drug originally developed by U.S. Gov, the CEO of GLSI bought the rights to the drug from the gov under the condition that GLSI would finish it’s development through all the clinical trials. The CEO notes this on a 2020 Benzinga video presentation.
6) MD Anderson Cancer Research facility in Houston, TX has performed all of
GLSI’s clinical trails, and is performing the final trial 3 as well. (MD Anderson = world’s best cancer research facility in the world, very difficult to get MD Anderson to accept performing clinical trials on a new biotech drug. Most biotech companies don’t have this resource, GLSI does.7) See price jump to $158 when the 1st half of data was presented at the American Association of Cancer Research in Dec 2020, showing 100% success over last 6 years in trails 1 & 2.
8) See video above of
GLSI C.E.O. on Benzinga PowerHour March 11 saying the evening of Thursday April 8 they will be releasing the 2nd half of the data (immune response data) from their American Association of Cancer Research presentation in April 2021. This is the last piece of data for GLSI to start phase III trials for FDA approval. MAJOR CATALYST! 9) Notice the stock price has been significantly increasing the past few days in anticipation of the immune response data being released April 8 evening. $150+ price estimate on Friday April 9.
10) My metrics give
GLSI a 93% probability of success getting FDA approval, with a price of $400-500+ once approved. Recent stock price moves show many others agree with my estimation.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.